Forgot Password?
Return to Course Listing

CME: The Current and Emerging Landscape of Adult Growth Hormone Deficiency (AGHD) Pharmacotherapy

Activity Description / Statement of Need:

Growth hormone deficiency (GHD), a condition characterized by inadequate endogenous production. When its onset occurs in adulthood, the etiology is related predominantly to oncologic causes (or their attendant treatment) in the vast majority of cases. In the United States, more than 50,000 adults are estimated to be growth hormone deficient, and 6,000 new cases are reported each year, inclusive of children with GHD who transition to adulthood (the prevalence of pediatric GHD is estimated to be between 1 in 4,000 and 1 in 10,000). One potential gap in care and source of confusion is the lack of a gold standard for diagnosis – due in large part to the wide range of potential causes in the individual presenting patient, but almost invariably, one from a variety of provocative pharmacologic stimulation test is selected.

Target Audience:

The following healthcare professionals: endocrinologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology; and any other healthcare professionals with an interest in or who clinically encounter patients with GHD.


This program is supported by an educational grant from Novo Nordisk.


Release Date: March 09, 2018 -- Expiration Date: March 16, 2020

Faculty: Kevin Yuen, MD

Agenda

A review primer: epidemiologic, pathophysiologic, etiologic features, and clinical signs and symptoms 

  • Common ground: definitions, background, statistics
  • Leading abnormalities and causes
  • Comorbidities and complications
  • The 2007 GH Society Consensus guidelines and 2011 Endocrine Society clinical practice guidelines – consensus, conjecture, and controversy then and in the years since
  • Clinical pearls, diagnostic practice guidance, and missed opportunities in patients’ presentations

Treatment options available for AGHD

  • Pharmacotherapy detailing: review, update, and emerging products
  • Best practices and clinical controversies
  • Monitoring parameters, counseling points, barriers to care, and patient education
  • Patient case(s)

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the challenges associated with diagnosis of AGHD
  • Identify current diagnostic tools for AGHD
  • Manage a patient with AGHD�s initial treatment regimen
  • Given a patient case, determine how and whether to adjust growth hormone replacement dosing
  • Describe present and emerging treatment options for AGHD

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure: Dr. Yuen, MD, FRCP(UK), FACE, Associate Professor of Medicine and Medical Director, Barrow Pituitary Center, Barrow Neurological Institute, University of Arizona College of Medicine, Phoenix, AZ, has received research grants from Pfizer, Novo Nordisk, Versartis, Teva Pharmaceuticals, OPKO Biologics, and Aerterna Zentaris; and has served on the advisory boards for Pfizer, Novo Nordisk, Sandoz, and Versartis


Disclosures of Educational Planners: Charles Turck, PharmD has no relevent financial disclosures.

 

Commercial Support Disclosure: This program is supported by an educational grant from Novo Nordisk.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Pediatric Growth Hormone Deficiency (PGHD): Therapeutic Updates, Present Clinical Controversies, and Barriers to Care